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Protein C inhibitor  is a plasma protein whose ability 
to inhibit activated protein C, thrombin, and other 
enzymes is  stimulated by heparin. These studies  were 
undertaken to further understand how heparin binds 
to protein C inhibitor  and how it accelerates  proteinase 
inhibition. The region of protein C inhibitor  from res- 
idues 264-283 was  identified as the  heparin-binding 
site. This differs from the putative heparin-binding 
site in the  related  proteins  antithrombin  and  heparin 
cofactor. The glycosaminoglycan specificity of protein 
C inhibitor  was  relatively  broad, including heparin  and 
heparan sulfate, but not dermatan sulfate. Non-sul- 
fated  and non-carboxylated polyanions also enhanced 
proteinase inhibition by protein C inhibitor.  Heparin 
accelerated inhibition of a-thrombin, TT-thrombin, ac- 
tivated protein C, factor Xa, urokinase,  and chymo- 
trypsin, but not plasma kallikrein.  The  ability of gly- 
cosaminoglycans to accelerate proteinase inhibition 
appeared to depend on the  formation of a ternary com- 
plex of inhibitor,  proteinase,  and glycosaminoglycan. 
The optimum heparin  concentration  for maximal rate 
stimulation  varied  from 10 to 100 pg/ml and  was  re- 
lated to the apparent affinity of the proteinase for 
heparin.  There  was no obvious relationship between 
heparin  affinity  and maximum inhibition rate  or de- 
gree of rate enhancement. The  affinity of the  resultant 
protein C inhibitor-proteinase complex was also not 
related  to inhibition rate enhancement, and  the  results 
showed that decreased heparin  affinity of the complex 
is not ap important part of the  catalytic mechanism of 
heparin.  The  importance of protein C inhibitor as a 
regulator of the  protein C system may depend on the 
relatively  large  increase  in  heparin-enhanced inhibi- 
tion rate for activated protein C compared to other 
proteinases. 
Hemostasis requires a balance between procoagulant and 
anticoagulant forces. Among the anticoagulant mechanisms 
is  the protein C system. Thrombin generated during coagu- 
lation binds to thrombomodulin on vessel walls and the 
thrombin-thrombomodulin complex activates the zymogen 
protein C. Activated protein C, with its cofactor protein S, 
proteolytically inactivates coagulant factors V and VI11 (1). 
The importance of the protein C system is demonstrated by 
the incidence of thrombosis in individuals who lack protein C 
(2) or protein S (3). The protein C system is believed to be 
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regulated by a plasma glycoprotein named protein C inhibitor, 
also known as plasminogen activator inhibitor-3 (4). Three 
other major plasma proteins, az-macroglobulin, az-antiplas- 
min,  and  a’-proteinase  inhibitor  inhibit activated protein C 
(5) but might be effective only by virtue of their relatively 
high concentration  in plasma. Protein C inhibitor reacts with 
the active site of activated protein C to form an essentially 
irreversible complex (6). Interestingly, protein C inhibitor 
also inhibits  thrombin, the final proteinase of the coagulation 
pathway, as well as  other procoagulant enzymes. This broad 
target  proteinase specificity of protein C inhibitor  presents  a 
problem in understanding the physiological importance of 
protein C inhibitor as a regulator of the protein C system. 
Direct evidence for the involvement of protein C inhibitor is 
lacking, as  an inhibitor deficiency has yet to be documented. 
Protein C inhibitor is a member of the serine proteinase 
inhibitor  (serpin)’ superfamily of proteins, whose prototype 
is a’-proteinase inhibitor (7). Protein C inhibitor can be 
further classified as  a heparin-binding serpin, along with the 
proteinase inhibitors antithrombin (historically known as 
antithrombin 111) and heparin cofactor (also called heparin 
cofactor 11). Heparin  and some other glycosaminoglycans act 
to increase the  rate of proteinase inhibition by these three 
plasma inhibitors,  in some cases as much as several thousand- 
fold ($). The mechansim whereby heparin catalyzes protein- 
ase inhibition is a subject of much study, especially  due to  the 
widespread use of heparin as  a  therapeutic anticoagulant. The 
ability of heparin to accelerate the inhibition of activated 
protein C by protein C inhibitor,  thereby favoring coagulation, 
is at odds with the anticoagulant effect of heparin therapy. 
As a  first  step toward understanding  this  apparent contradic- 
tion and in order to gather insight into the physiological 
importance of protein C inhibitor, a series of studies was 
undertaken. The work presented here describes the heparin- 
binding site of protein C inhibitor, the polyanion specificity 
of protein C inhibitor,  and the mechanism whereby heparin 
accelerates proteinase  inhibition. Some of these results have 
appeared previously in abstract form (9). The following report 
compares protein C inhibitor to antithrombin and heparin 
cofactor (10). 
EXPERIMENTAL  PROCEDURES 
Materiab-Human protein C inhibitor was purified as previously 
described ( l l ) ,  as were antithrombin and heparin cofactor (12). All 
proteinases were  of human origin, with the exception of bovine 
chymotrypsin. a-Thrombin was purified as described (13) or con- 
verted to ?,-thrombin (14). Protein C was prepared as a by-product 
of the factor X  preparation (15), and further purified and activated 
by incubating it with thrombin, then passing the mixture over im- 
mobilized antithrombin to remove thrombin and traces of factor Xa. 
Urokinase was purchased from Sigma, plasma kallikrein from Calbi- 
HEPES, 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid; PEG, 
The abbreviations used are: serpin, serine proteinase inhibitor; 
polyethylene glycol; HPLC, high performance liquid chromatography. 
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ochem, bovine chymotrypsin from Cooper Biomedical, and neutrophil 
elastase from Elastin  Products (Pacific, MO). The following protein- 
ase substrates were used Chromozym TH (tosyl-Gly-Pro-Arg-p-ni- 
troanilide) for thrombin from Boehringer Mannheim, Spectrozyme 
PCa (Lys(Cbo)-Pro-Arg-p-nitroanilide) for activated protein  C and 
Spectrozyme FXa (MeO-CO-CHG-Gly-Arg-p-nitroanilide) for factor 
Xa from  American Diagnostica, S-2444 (Glu-Gly-Arg-p-nitroanilide) 
for urokinase and S-2302 (Pro-Phe-Arg-p-nitroanilide) for kallikrein 
from KabiVitrum, and Suc-Ala-Ala-Pro-Phe-p-nitroanilide for chy- 
motrypsin from  Sigma. The following were purchased from Sigma: 
bovine serum albumin, polybrene (1,5-dimethyl-1,5-diazaundecame- 
thylene polymethobromide), bovine heparan sulfate, bovine chon- 
droitin sulfate A, shark chondroitin sulfate C, fucoidan (a sulfated 
polymer of fucose  from a marine alga), phosvitin (a phosphoserine- 
containing glycoprotein from egg yolk), sulfatides, and tetrapoly- 
phosphate. Unfractionated heparin was from Diosynth (Oss, the 
Netherlands). Low molecular weight (M, 5500) heparin was from 
Calbiochem. Dermatan sulfate was purchased from Calbiochem and 
treated with nitrous acid to remove contaminating heparin (16). 
DSPG I1 (a dermatan sulfate proteoglycan from bovine skin) was the 
gift of Dr. Lawrence Rosenberg, Montefiore Hospital, Bronx, NY. 
Heparin fractions with low and high affinity for antithrombin were 
the gift of Dr. Ingemar Bjork, Swedish University of Agricultural 
Sciences Uppsala, Sweden. Chemically depolymerized heparin (av- 
erage molecular weight 5000, 3500, and 2500) was the gift of Dr. 
Charles Griffin, Miami University, OH. Fmoc-amino acids were from 
MilliGen. Heparin-Sepharose was from Pharmacia  LKB Biotechnol- 
ogy Inc. and heparin-agarose was prepared as described (12). 
Peptide Synthesis-Peptides were assembled from Fmoc amino 
acids using a Milligen pepsynthesizer according to  the reported cDNA 
sequence of protein C  inhibitor (17). In peptide 1-16, tyrosine was 
added to the carboxyl terminus, and in peptide 80-93, Phe-92 was 
substituted with tyrosine to facilitate spectrophotometric quantita- 
tion of the peptides. Purity of the peptides was verified by reverse- 
phase  HPLC, and when necessary, further purification was accom- 
plished by HPLC. Heparin affinity of peptides was measured using a 
1-ml column of heparin-agarose in 20 mM HEPES, 0.1% PEG 8000, 
pH 7.4, with a linear salt gradient. 
Peptide Competition Assays-Peptides (0.1-100 FM) in 20  mM 
HEPES, 150 mM NaCl, 0.1% PEG, pH 7.4, were added to assay 
mixtures containing 1 pg/ml heparin, 2 mg/ml bovine serum albumin, 
and 50 or 100 nM protein C  inhibitor in the same buffer a t  25 "C. 
Reactions were started with the addition of 5 nM thrombin or 10 nM 
activated protein C. After incubation, remaining proteinase activity 
was measured using 0.15 mM chromogenic substrate with 2 mg/ml 
Polybrene. Substrate hydrolysis was linearly related to proteinase 
concentration. Control experiments verified that none of the peptides 
affected either the ability of proteinase to hydrolyze substrate  or the 
ability of protein C  inhibitor to inhibit proteinases in the absence of 
heparin. 
Polyanion  Acceleration of Protein  C Inhibitor Activity-Polyanions 
were dissolved in 20 mM HEPES, 150 mM NaC1,  0.1% PEG,  pH 7.4, 
and various concentrations (0.1-1000 pg/ml) were added to 60 nM 
protein  C inhibitor and 2 mg/ml bovine serum albumin in the same 
buffer at 25 "C. Reactions were started with the addition of 5 nM 
thrombin or activated protein C, incubated for various times, and 
remaining proteinase activity was measured. Control experiments in 
the absence of protein C  inhibitor verified that none of the polyanions 
directly affected the ability of proteinase to hydrolyze substrate. 
Second order proteinase inhibition rate  constants were calculated as 
-In a/t [protein C inhibitor] where a is the fractional proteinase 
activity remaining relative to  the uninhibited control, t is the time of 
incubation, and [protein  C inhibitor] is the inhibitor  concentration, 
60 nM. The inhibition rate increase was calculated by dividing the 
maximum inhibition rate in the presence of polyanion by the  rate in 
the absence of polyanion, and  the optimum polyanion concentration 
was the concentration that produced the maximum inhibition rate. 
Heparin Acceleration of Proteinase Inhibition-Heparin (0.1-1000 
pg/ml) was added to 50 nM protein C  inhibitor  in 20 mM HEPES, 
150 mM NaC1, 0.1% PEG, pH 7.4, containing 2 mg/ml bovine serum 
albumin at 25 "C. Reactions were started by adding 5 nM proteinase 
(a-thrombin, yT-thrombin, activated protein C, factor Xa, urokinase, 
plasma kallikrein, or chymotrypsin). Incubation times varied among 
proteinases and remaining proteinase activity was determined by 
substrate hydrolysis. Proteinase inhibition rate  constants were cal- 
culated as described above. 
Heparin Affinity Chromatography-Experiments were performed 
using a Pharmacia fast protein liquid chromatography system and a 
5-ml column of heparin-Sepharose in 20 mM HEPES, 10 mM NaC1, 
0.1% PEG,  pH 7.4. Samples of protein  C inhibitor, proteinase, and 
protein C inhibitor-proteinase complexes were eluted with a 1 ml/ 
min linear  salt gradient from 10 mM to 1.2 M NaCl; 0.25-ml fractions 
were collected. Proteins were detected by absorbance at 280 nm and 
by reactivity with a  rabbit polyclonal antiserum to protein  C inhibitor 
(to detect protein C inhibitor and protein C inhibitor-proteinase 
complexes) and by chromogenic substrate hydrolysis (to detect pro- 
teinases and protein  C  inhibitor-proteinase complexes; an extended 
incubation time was required to detect proteinase activity in com- 
plexes). Results were plotted and  the  salt concentration correspond- 
ing to peak elution was determined. The mean and standard deviation 
were calculated from multiple runs (2-10)  of each sample. Protein C 
inhibitor-proteinase complexes were prepared by incubating protein- 
ase with a slight excess of protein  C  inhibitor for a time previously 
determined to allow complete reaction, at least five times the half- 
life of the reaction. Inactivation of protein C inhibitor by neutrophil 
elastase was  followed by the loss of thrombin inhibition activity. 
RESULTS 
Identification of the Heparin-binding Site of Protein C In- 
hibitor-Because heparin is a negatively charged glycosami- 
noglycan, it is expected to bind to basic residues of protein C 
inhibitor. Three regions were identified as  potential heparin- 
binding sites: residues 1-11, 82-90, and 266-278. Residues 
266-278 were  previously identified as a heparin-binding site 
by homology to a consensus glycosaminoglycan recognition 
site (18). Peptide 1-11 also follows the consensus sequence. 
Sequences corresponding to  the  three regions of protein C 
inhibitor (1-16,80-93, and 264-283, and  the 264-283 random 
sequence) are shown in Fig. 1, along with helical-wheel pro- 
jections of these sequences (19). The projections show that 
the selected sequences can form amphipathic helices with 
basic and uncharged residues on opposite faces of the helix. 
To  test whether the selected sequences represent the hep- 
arin-binding site of protein C inhibitor, the  three peptides 
were synthesized and  their ability to bind heparin was tested 
in proteinase inhibition assays. The peptides were added to 
systems containing protein C inhibitor, proteinase, and hep- 
arin; with the premise that heparin-binding peptides would 







RANDOM PEPTIDE -283 
FIG. 1. Potential heparin-binding regions of protein C in- 
hibitor. Three regions rich in basic residues were selected and 
peptides corresponding to these regions were synthesized. The se- 
quences of the peptides are shown along with helical wheel diagrams 
of the sequences (assuming 3.6 residues/helical turn). In peptide 1- 
16, a tyrosine residue not found in native protein C inhibitor was 
added to  the carboxyl terminus.  In peptide 80-93, Phe-92 was replaced 
with tyrosine in the synthetic peptide. The random sequence peptide 
was constructed using the same residues as peptide 264-283, but  in 
random order. The first and last residues of peptide 264-283 and the 
random sequence peptide are  not visible in the helical wheel diagrams. 
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the rate of the proteinase inhibition reaction. The results 
revealed that of the three peptides, only peptide 264-283 
competed with protein  C  inhibitor for binding to heparin, as 
shown by the increase in  proteinase activity with increasing 
peptide concentration (Fig. 2). This effect was observed for 
both  thrombin  and activated protein C. A peptide comprised 
of the same residues as peptide 264-283, but in random 
sequence, did not compete as effectively, suggesting that  the 
three-dimensional distribution of charged residues rather 
than  the number of charged residues was responsible for its 
heparin binding function. As further confirmation of peptides 
as models for the heparin binding region in  proteins, peptide 
264-283 interfered with heparin-catalyzed inhibition of 
thrombin by  two other heparin-binding inhibitors,  antithrom- 
bin  and heparin cofactor, and peptides corresponding to  the 
putative  antithrombin heparin-binding site (Ala-124-Leu- 
140, Ref. 10 ) competed for heparin binding in the protein  C 
inhibitor assay (results not shown). Furthermore, peptide 
264-283 bound to immobilized heparin and was eluted with 
800 mM NaC1, indicating even higher affinity than native 
protein C inhibitor (elution at approximately 500 mM NaC1) 
The random sequence peptide bound less tightly  (elution at 
380 mM NaC1,  Ref 10). 
Polyanwn Specificity of Protein C Inhibitor-In addition to 
heparin, some other glycosaminoglycans have been found to 
accelerate proteinase inhibition by protein C inhibitor (20, 
21). To further assess the specificity of protein  C  inhibitor, 
we tested the ability of various polyanions to catalyze protein 
C inhibitor inhibition of thrombin  and  activated  protein C. 
Each polyanion was tested at various concentrations  in order 
to determine the maximum degree of rate  enhancement  and 
the polyanion concentration at which that occurred. The 
results are presented in Table I. Among the mammalian 
glycosaminoglycans,  only heparin,  heparan sulfate, and chon- 
droitin sulfate A caused acceleration of thrombin and acti- 
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FIG. 2. Peptide competition in proteinase inhibition assays. 
Synthetic peptides corresponding to potential heparin-binding re- 
gions in protein C  inhibitor (shown in Fig. 1) were added to thrombin 
(panel A )  or activated protein C (panel B )  inhibition assays as 
described under “Experimental Procedures.” They axes show throm- 
bin  and protein C activity relative to  the activity in the absence of 
inhibitor.  Greater proteinase activity indicates diminished inhibition 
due to peptides competing with proteins for heparin binding. B, 
peptide 1-16; 0, peptide 80-93; +, peptide 264-283; 0, random peptide 
264-283. 
TABLE I 
Polyanwn acceleration of proteinuse inhibition by protein C inhibitor 
Thrombin  Activated  protein C 
Polyanion  Optimum  Rate  Optimum  Rate 
(polyanion)”  increaseb  (polyanion)  increase 
d m 1   d m 1  
Heparin 10 9.4 100 52.2 
Heparan sulfate 100 1.9  3 0 3.1 
Chondroitin sulfate A >lo00 1.7 >lo00 4.1 
Chondroitin sulfate C ND‘ ND 
Fucoidan 10 9.5 100 10.0 
Dermatan sulfate ND >lo00 4.6 
DSPG I1 ND ND 
Phosvitin 30 1.6 100 5.4 
AT low affinity hepa- 30 3.0 100 10.3 
AT high affinity hepa- 30 3.5 100 8.7 
Low molecular weight 10 2.6 30 12.1 
Heparin M ,  5000 3 1.2  0  10.2 
Heparin M ,  3500 10 1.5 100 12.5 




“The optimum polyanion concentration is the concentration at 
* The  rate increase is calculated as  the ratio of the maximum rate 
e ND, no acceleration of inhibition detected at 1 mg/ml polyanion. 
vated protein  C inhibition by protein C  inhibitor, although 
the effect of chondroitin sulfate A was  weak, as shown by the 
high concentration required to increase the inhibition rate. 
Dermatan sulfate showed  no activity with thrombin  and very 
low activity with activated protein C; a highly purified der- 
matan sulfate preparation  (DSPG 11) showed no activity with 
either proteinase. Chondroitin sulfate C did not accelerate 
inhibition. Interestingly, fucoidan (a sulfated polymer of fu- 
cose from a marine alga) was relatively effective, and phos- 
vitin (a phosphoserine-containing glycoprotein from egg yolk) 
was also active. Sulfatides and tetrapolyphosphate did not 
affect the rate of proteinase inhibition by protein  C  inhibitor 
(not shown). 
A number of heparin fractions accelerated inhibition of 
thrombin and activated protein C by protein C inhibitor 
(Table  I).  Protein  C  inhibitor clearly differs from antithrom- 
bin in responding equally well to heparin with high or low 
affinity for antithrombin.  Protein  C  inhibitor exhibited some 
specificity for the size of the heparin molecule, as greater 
concentrations of the smaller heparin fractions were required 
for maximum stimulation of the inhibition reaction. 
Mechanism of Heparin Acceleration of Inhibition-The 
mechanism whereby heparin accelerates proteinase inhibition 
by protein  C  inhibitor could depend on heparin binding to  the 
inhibitor, to  the proteinase, or to both proteins. Examination 
of the effect of increasing concentrations of heparin on the 
rate of inhibition of six different proteinases (a-thrombin, Y ~ -  
thrombin, activated protein C, factor Xa, urokinase, and 
chymotrypsin, Fig. 3) reveals a bell-shaped curve that is 
consistent with a  ternary complex  model for heparin action 
(22-24).  According to  this model, heparin binds  both  inhibitor 
and proteinase to bring the reactants  into closer proximity, 
and  the rate of reaction increases as heparin concentration 
increases. When heparin concentrations increase beyond a 
certain  point, the proteinase  and  inhibitor  are more  likely to 
bind to separate heparin molecules, thus decreasing the  cat- 
alytic efficiency of the glycosaminoglycan. If heparin binding 
to only one of the two reactants were important,  then heparin 
would exhibit a  saturation phenomenon in these experiments. 
The optimum heparin concentration  as well as  the relative 
which the maximum proteinase inhibition rate occurs. 
to  the rate  in the absence of polyanion. 
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TABLE I1 
Proteinase  heparin affinity and inhibition rate increase 
Proteinase 
affinity” optimumb rate increase‘ 
Heparin Heparin Maximum Rate 
1 10 loo 
Heparin (pg/rnl) 
I 
1 10 100 
Heparin (pg/rnl) 
FIG. 3. Heparin acceleration of proteinase inhibition by 
protein C inhibitor. The effect of heparin on the rate of inhibition 
was measured as described  under “Experimental  Procedures.” Panel 
A:  W, a-thrombin; 0, 7,-thrombin; +, activated  protein C. Panel B: 
W, factor Xa; 0 urokinase; +, plasma kallikrein; 0, chymotrypsin. 
The y axis shows the relative  inhibition rate, the ratio of the rate 
constant at a particular  heparin  concentration to the rate constant 
in the absence of heparin. 
increase in inhibition  rate varied among  different  proteinases. 
All experiments were performed with  identical  concentrations 
of protein C inhibitor and proteinase in order to rule out 
protein  concentration-dependent effects on  heparin  optimum 
or maximum rate.  Interestingly,  the  rate of inhibition of factor 
Xa was diminished at  low heparin concentrations, and at 
optimum  heparin  the  rate was  only  slightly greater  than  the 
rate  in  the  absence of glycosaminoglycan. In  addition,  increas- 
ing  concentrations of heparin progressively  decreased the  rate 
of inhibition of plasma  kallikrein by protein C inhibitor (Fig. 
3). These two  cases  suggest that  the  catalytic effect of heparin 
on  protein C inhibitor  reactivity  is  not a simple phenomenon, 
but might involve additional effects of heparin  on  the  partic- 
ular  inhibitor-proteinase  pair. 
The failure of attempts  to  demonstrate  the  importance of 
simultaneous binding of both inhibitor and proteinase to 
heparin using a kinetics approach (25, 26) was most likely 
due to the fact that heparin elicited a relatively mild rate 
increase. This  meant  that  rate  enhancement was not  detect- 
able under the required conditions, where proteinase and 
inhibitor concentrations must saturate a small amount of 
heparin. 
Heparin  affinity  chromatography was used  to  further  assess 
the contribution of heparin  binding to  protein C inhibitor  and 
various  proteinases before and  after  the  inhibition  reaction. 
Protein C inhibitor and five proteinases (a-thrombin, acti- 
vated protein C, factor Xa, urokinase, and chymotrypsin) 
bound  to immobilized heparin  and were eluted by salt concen- 
trations  greater  than physiological (290-640 mM NaC1, Table 
11). Therefore,  in  inhibition  assays  (containing 150mM NaC1) 
heparin  binding would occur. Table I1 demonstrates  the  in- 
verse relationship between the  apparent  heparin  affinity of a 
particular  proteinase  and  the  heparin  concentration required 
for maximum inhibition  rate  enhancement; for  example, hep- 
Thrombin 640 f 27 10 11.2 9.4 
Factor Xa 446 f 19 30  0.21 1.1 
Activated protein C 357 f 7 100 1.54 52.2 
Urokinase 344 f 7 100 0.02 2.3 
Chymotrypsin 2 9 0 f  28 100 203 3.0 
a Heparin  affinity is given as the salt concentration  required for 
peak elution from immobilized heparin. This value is an indication 
of heparin  affinity, not a true  affinity constant. 
The optimum  heparin  concentration is the concentration at which 
the maximum inhibition  rate  occurs. 
The rate increase is calculated as the ratio of the maximum rate 
to the rate in the absence of heparin. 
TABLE I11 
Heparin  affinity of protein C inhibitor and protein C inhibitor- 
proteinase complexes 
Inhibitor-proteinase complex Salt conc. at peak elution“ 
mM NaCl 
Protein C inhibitorb 508 f 11 
Protein C inhibitor-thrombin 562 f 15 
Protein C inhibitor-activated  protein C 448 f 25 
Protein C inhibitor-factor Xa 525 f 17 
Protein C inhibitor-urokinase 422 f 28 
The salt concentration required for peak elution from immobilized 
‘Protein C inhibitor affinity was measured in the absence of 
heparin. 
proteinase. 
arin was  most  efficient at catalyzing  the  inhibition of throm- 
bin, which had the highest heparin affinity. There is no 
obvious relationship between heparin  affinity  and  the maxi- 
mum  rate of inhibition or the degree of rate  enhancement. 
Kallikrein, which exhibited  no  inhibition  rate  enhancement, 
did  bind  to immobilized heparin, eluting a t  305 mM NaCl. 
The  salt  concentration  at which  a protein  elutes  from  heparin 
is an  indication of heparin  affinity  and  is useful  for compar- 
ative purposes, but  is  not  identical  to  an  affinity  constant, 
which requires more  rigorous measurement. 
Table I11 describes the  apparent  heparin  affinity of protein 
C inhibitor following reaction with four proteinases. The 
reaction between protein C inhibitor  and  its  target  proteinases 
results  in a stable bimolecular complex (6). Complexes con- 
taining  protein C inhibitor  and  one of four proteinases were 
applied to immobilized heparin. The protein C inhibitor- 
thrombin complex eluted at higher salt  concentration  than 
protein C inhibitor alone, most likely due  to  the  contribution 
of thrombin, whose affinity for heparin was even  higher. The 
protein C inhibitor-factor  Xa complex eluted at  essentially 
the same salt concentration as protein C inhibitor alone, 
although  the  affinity of factor  Xa itself  was lower than  that 
of protein C inhibitor.  The  other complexes, protein C inhib- 
itor-activated protein C and protein C inhibitor-urokinase, 
showed heparin  affinities  intermediate  to  those of protein C 
inhibitor and the individual proteinase. I t  is obvious from 
these  results  that  there  is  no  uniform decrease in  apparent 
heparin  affinity of protein C inhibitor following reaction  with 
proteinase.  Nor does the  change  in  heparin  affinity  correlate 
with the degree of inhibition rate enhancement caused by 
heparin  (listed  in  Table 11). Protein C inhibitor  inactivated 
with  neutrophil  elastase, presumably at or near  the reactive 
site,  eluted  from  heparin-Sepharose at  530 f 14 mM NaC1. 
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DISCUSSION 
These  studies were undertaken  in order to better  under- 
stand how heparin binds to protein C inhibitor  and how this 
is important for the physiological function of protein C inhib- 
itor. The results focus on  three areas: identification of the 
putative heparin-binding site of protein C inhibitor, the gly- 
cosaminoglycan specificity of protein C inhibitor, and the 
mechanism whereby heparin accelerates proteinase inhibi- 
tion. A region of the protein C inhibitor molecule, residues 
264-283, was identified as the heparin-binding site. This 
sequence can be represented as  an amphipathic helix, with 
basic and uncharged residues on opposite faces of the helix, 
which is a property of other heparin-binding peptides (18). A 
synthetic peptide corresponding to this region  of protein C 
inhibitor bound to heparin and interfered in heparin-cata- 
lyzed proteinase inhibition. This sequence, located in the H 
helix of protein C inhibitor (7), clearly differs from the hep- 
arin-binding  sites of the related proteins  antithrombin  and 
heparin cofactor, which have been assigned primarily to  the 
D helix on the basis of chemical modification experiments 
and natural mutations (7). The present results also differ 
from a recent report implicating the amino terminus of pro- 
tein C inhibitor  (the A+ helix) in heparin binding (27). Failure 
to detect heparin binding of synthetic peptide 1-16 in the 
present experiments could  be due to  the assumption that  the 
protein C inhibitor heparin-binding site is simply a linear 
sequence of residues and  that synthetic peptides would adopt 
the same structure  (and therefore function)  as the sequences 
in  the native protein. It is also possible that  the monoclonal 
antibody used in the previous study, which bound to helix 
A+, might interfere with heparin binding to  the H helix; this 
is certainly a possibility if the A+ and  the H helices together 
form a heparin-binding site,  as was suggested (27). 
Acceleration of protein C inhibitor  proteinase inhibition by 
a variety of glycosaminoglycans (especially heparin, heparan 
sulfate, fucoidan, and low molecular weight heparin)  and  other 
polyanions (phosvitin) is consistent with a relatively nonspe- 
cific heparin-binding site in protein C inhibitor. This is in 
contrast  to  antithrombin, which exhibits narrow specificity 
for heparin and  heparan sulfate (28). Protein C inhibitor more 
closely resembles heparin cofactor, which allows an even wider 
variety of polyanions to accelerate thrombin  inhibition (29- 
31). Previous studies noted the ability of several sulfated 
glycosaminoglycans to enhance  protein C inhibitor activity, 
although no effect of heparan sulfate was detected (20, 21). 
The ability of fucoidan (which contains no carboxyl groups) 
and phosvitin (which contains no sulfate groups) to enhance 
proteinase inhibition by protein C inhibitor is further evi- 
dence for a relatively nonspecific glycosaminoglycan-binding 
site in protein C inhibitor. Interestingly, the “permissive” 
glycosaminoglycan-binding site of protein C inhibitor did not 
accommodate dermatan sulfate well; this glycosaminoglycan 
is the most effective at increasing the inhibition rate of 
heparin cofactor (32). The identity of the glycosaminoglycan 
that accelerates thrombin or activated protein C inhibition 
by protein C inhibitor in vivo remains a mystery, although 
heparan sulfate, which lines vessel  walls and is believed to be 
the primary antithrombin-activating glycosaminoglycan (28), 
is a candidate. Protein C inhibitor, however, did not  distin- 
guish heparin of high or low affinity for antithrombin. The 
low activity of chondroitin sulfate A measured in this study 
could be due to heparan sulfate contamination,  as this glycos- 
aminoglycan was not treated with nitrous acid to destroy 
traces of heparin (16). The present  study is at odds with a 
recent report that dermatan sulfate from various sources 
accelerated inhibition of urokinase by protein C inhibitor 
(33).* The chemical heterogeneity and difficult purification of 
glycosaminoglycans from different tissues and species could 
contribute to  the discordant findings. 
The degree of acceleration of activated protein C or throm- 
bin inhibition by protein C inhibitor varied with the polyan- 
ion. In  any case, the increase in rate is relatively mild  when 
protein C inhibitor is compared to antithrombin or heparin 
cofactor (IO), although the increase in rate  appears to depend 
on the particular reaction conditions, as different results have 
been reported for the heparin enhancement of protein C 
inhibitor activity (11, 34). The experiments in the present 
study were performed with constant  concentrations of pro- 
teins in order to facilitate comparisons among polyanions. 
The concentration of a polyanion required for  maximum rate 
enhancement also varied; this most likely reflects the affinity 
of the glycosaminoglycan for protein C inhibitor and the 
proteinases. Among the polyanions tested, the optimum con- 
centrations varied in parallel for thrombin and activated 
protein C inhibition; this suggests a specific interaction of the 
polyanions with the inhibitor. 
The effect of various concentrations of heparin on the rate 
of inhibition of five proteinases  (thrombin, factor Xa, acti- 
vated protein C, urokinase, and chymotrypsin) by protein C 
inhibitor was consistent with the ternary complex  model (22) 
in which both proteinase and  inhibitor bind to  the glycosa- 
minoglycan. This phenomenon has been observed previously 
for protein C inhibitor (20, 21, 34) and is well-characterized 
for the related inhibitors  antithrombin  and heparin cofactor. 
Most of the polyanions that stimulated proteinase inhibition 
in the present study and in other  reports appear to follow the 
same mechanism. In no case was a  saturation effect observed, 
although it is difficult to completely rule out  this possibility 
in cases where stimulation is weak and polyanion concentra- 
tions  cannot be increased further. 
This work represents a further attempt to correlate the 
mechanism of heparin action with heparin binding properties 
of the proteins involved. The heparin concentration required 
for maximum inhibition rate enhancement is a function of 
the apparent affinity of the proteinase for heparin, but  there 
appears to be  no general rule governing the magnitude of the 
maximum rate or the  rate increase. The rate of inhibition of 
factor Xa was actually decreased at low concentrations of 
heparin, and  the rate of inhibition of plasma kallikrein pro- 
gressively decreased with increasing heparin. One explanation 
for these results is that in the case of thrombin, activated 
protein C, urokinase, or chymotrypsin, the primary role of 
heparin is to bind  both  inhibitor  and proteinase to bring them 
into close proximity for more rapid reaction than in the 
absence of heparin. However, in the case of factor Xa  and 
kallikrein, other factors such as ionic interactions, confor- 
mational changes, or steric hindrance might partially or com- 
pletely offset the rate enhancement due to the proximity 
effect. Different heparin-enhanced  rate  constants have  been 
reported previously (6, 11, 34); some of the differences are 
most likely due to reaction conditions, particularly tempera- 
ture and protein concentration, as well as the source of 
heparin. The concentrations of inhibitor  and proteinase have 
been shown to influence the optimum heparin concentration 
and maximum rate  enhancement (26). In  the  present study 
experiments with different proteinases were performed with 
the same protein  concentrations to eliminate other variables. 
It has been reported that  the inhibition of activated protein 
We found that dermatan sulfate that had not been treated with 
nitrous acid to destroy contaminating heparin did accelerate uroki- 
nase inhibition by protein C inhibitor, but acid-treated dermatan 
sulfate had no effect on the urokinase inhibition rate. 
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C by aprotinin is enhanced by heparin (35); this suggests that 
heparin might directly affect the catalytic properties of acti- 
vated protein C. Inhibition of activated protein  C by protein 
C inhibitor is accelerated by heparin to a much greater degree 
than for any other proteinase tested, although no effect of 
heparin on hydrolysis of a small peptide substrate by activated 
protein C was detected in the present study. 
It has been proposed that  part of the ability of heparin to 
dramatically accelerate thrombin inhibition by antithrombin 
is due to the decreased heparin affinity of the resultant 
antithrombin-thrombin inhibitory complex, which allows 
heparin to efficiently dissociate from the proteins in order to 
participate in additional rounds of catalysis (36). (Native 
antithrombin eluted from heparin-Sepharose at 925 mM 
NaC1, while the antithrombin-thrombin complex and anti- 
thrombin inactivated at  the reactive site by neutrophil elas- 
tase eluted at 430 mM NaCl, in agreement with a previous 
report (36); results  not shown.) This phenomenon is probably 
less important for protein C  inhibitor inhibition of protein- 
ases, as there was no consistent correlation of maximum 
inhibition rate  or  rate  enhancement with changes in apparent 
heparin affinity of different protein C inhibitor-proteinase 
complexes. The absence of a change in heparin affinity of the 
protein C inhibitor-activated protein C complex has been 
previously noted (37). 
In conclusion, protein C inhibitor clearly belongs to  the 
group of serpins whose reactivity toward certain  proteinases 
is stimulated by heparin. (A comparison of three of these 
proteins is contained in the following paper, Ref. 10.) The 
mechanism of heparin acceleration of proteinase inhibition 
by protein C inhibitor was consistent with a  ternary complex 
model, but  there were indications that  the exact mechansim 
is  a more complicated function of the particular  proteinase 
involved, as shown by the large rate  enhancement for acti- 
vated protein C inhibition relative to other proteinases. The 
question remains how protein C inhibitor can regulate the 
anticoagulant protein C system when it is also an inhibitor of 
procoagulant enzymes. So far there is little evidence for a 
protein C system-specific glycosaminoglycan that might pref- 
erentially accelerate activated protein C inhibition, since all 
of the polyanions tested in the present study stimulate  inhi- 
bition of both thrombin and activated protein C. It is also 
possible that additional factors, such as the relative concen- 
trations of activated protein C, thrombin,  and  other enzymes 
or their localization in. uiuo, are critical for determining the 
physiological effectiveness of protein C inhibitor. 
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